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ABSTRACT
Natural killer (NK) cells are lymphocytes of the innate immune system which do
not require prior priming to target infected or altered-self cells, such as tumour
cells. The basic functions of NK cells include cytotoxicity and cytokine
production. These cells possess numerous activating and inhibitory receptors
which regulate their function based on a signalling balance. In mice, NK cells
possess NKR-P1B inhibitory receptors which recognize the C-type lectin-related
protein-b (Clr-b) ligand. This ligand is present on healthy self cells and may be
used by cancer cells to evade NK cell effector functions. The disruption of the
NKR-P1B:Clr-b axis has been previously shown to delay tumour onset and
progression in a B cell lymphoma model, indicative of cancer immunoevasion by
means of this inhibitory axis. This research aimed to assess the role of the NKRP1B:Clr-b axis in mammary tumour immunosurveillance. E0771 mammary
adenocarcinoma induced-tumours which were Clr-b-sufficient and -deficient were
used as a tumour model to evaluate mammary tumour onset and growth, as well as
tumour-infiltrating NK (TINK) cell phenotype in WT and NKR-P1B deficient
(Nkrp1b-/-) B6 mice. Nkrp1b-/- mice were found to have a delayed growth and
development of mammary tumours. TINKs of Nkrp1b-/- mice also appeared to
possess more of an exhausted phenotype in comparison to their WT counterparts.
The findings indicate that the NKR-P1B:Clr-b axis plays a role in NK cellmediated immunosurveillance of mammary tumours, while regulating NK cell
exhaustion in tumours.
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INTRODUCTION
In recent years, breast cancer has been one of the leading causes of premature
death worldwide.1–3 Due to the complex nature of cancer, it does not respond well to
many available treatments. This has led to the development of novel treatment regiments,
with recent advances in immunotherapy, which employs the host’s immune system
against the cancer cells. Natural killer (NK) cells carry great potential in the immune
responses against cancer since they do not require priming to employ their immune
response. However, cancer cells may evade the cytotoxic effects of NK cells by
mimicking the host’s healthy cells and signalling an inhibition of NK cells. This project
aims to assess how NK cell-mediated anti-tumour activity is affected by the NK cell
inhibitory axis between the NKR-P1B receptor and its cognate ligand, Clr-b.
Natural killer cells
Natural killer cells are immune cells derived from the common lymphoid
progenitor alongside B and T cells. These cells belong to group 1 of the innate lymphoid
cells (ILC1) and function in the immune system, specifically the innate immune system,
although they may possess some adaptive roles. NK cells are special in that they do not
require prior sensitization in order to achieve effector function and are involved in
defence against altered or stressed cells, especially seen in instances of viral infections
and cancers.
NK cells represent 5-20% of the circulating lymphocytes in humans 4. According
to Melsen et al. 2016, the lymph nodes contain approximately 40% of the lymphocytes in
the body and 2-5% of these are NK cells.5 Lymphoid tissue NK cells (ltNK) represent
60% of all NK cells, and the possess less potent cytotoxic roles in comparison to other
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NK cells. In the spleen and bone marrow, NK cells constitute 5-20% and 4% of the
respective lymphoid organs.
History and Discovery
NK cells have only recently become a heavily researched topic of investigation in
immunology. In fact, prior to the 1970s, lymphocytes were only classified as one of two
types: T cells or B cells.6 NK cells are large granular lymphocytes pertaining primarily
belonging to the innate immune system, originally discovered based on their lack of B
and T cell surface markers.7 The cells were originally named N-cells and were discovered
for their natural cytotoxic effects against leukemia-associated antigens8 and it was
proposed that these uncharacterized lymphocytes were able to survey tumours through an
undescribed mechanism. These cells were further investigated in 1975 by separate
studies, when mice infected with the oncogenic murine leukemia virus (MLV) possessed
the same cytotoxic cells targeting the leukemia cells and researchers named them natural
killer cells due to their apparent non-specific cytotoxicity.9,10
Classification
The criteria by which NK cells have been classified have been evolving since
their discovery, as new cell-specific antigens were discovered at various stages of
development. Current NK cell markers used to characterize human NK cells are CD56
and CD16, and the lack of expression of T cell receptor (TCR) or CD3.11 CD56 is neural
cell adhesion molecule (NCAM), and its function is not completely understood. CD16 is
the Fc receptor (FCγRIII) which allows for NK cells to perform a phenomenon coined
antibody-dependent cellular cytotoxicity (ADCC) and is the first antigen used to identify
NK cells. Two subsets of NK cells can be identified in humans based on the level of
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expression of CD56. In the blood, CD56dim cells predominate, but the CD56bright cells
predominate in the body due to their increased expression in peripheral and lymphoid
tissue.11 These markers typically describe the maturation of the NK cells, with CD56dim
cells pertaining to a more mature phenotype in comparison to the CD56bright phenotype,
however the exact development is still being investigated.11 CD56bright cells, the alleged
immature NK cells, were found to produce high amounts of IFN-γ and TNF-⍺, proinflammatory cytokines, indicating that they play a more important role in the
recruitment of other effector cells 11.
In mice, NK cells are primarily characterized by the presence of the antigen
NK1.1 (also known as CD161 or activating receptor NKR-P1C).12 NK cells are also
differentiated based on their expression of CD27 and CD11b,13 along with other markers
that can help determine the developmental phenotype of NK cell subsets.
Development
Developmental stages of NK cells are completed in the bone marrow. NK cell
development is split into four major stages, the common lymphoid progenitor (CLP),
natural killer cell progenitor (NKP), immature natural killer cells (iNK) and mature
natural killer cells (mNK). The transition from CLP to NKP is marked through the
acquisition of CD122, or the IL-2 β receptor chain.14 Following this, changes enable NK
cells to transition to the iNK phenotype. These include the acquisition of integrins in the
order of ⍺v, DX5 and Mac-1 (CD11b).15
NK cells develop from the common lymphoid progenitor (CLP) along with B and
T cells, originating from the hematopoietic stem cell (HSC).16 The developmental stages
of the NK cell are described by Geiger & and Sun, 2016 to include the CLP, Pre-NKP,
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NKP, iNK and mNK stages. The CLP, which expresses c-kit and FLT3 (receptors which
promote proliferation and differentiation), along with IL-7 receptor-⍺ (IL-7R) and CD27
(a member of the tumour necrosis factor receptor superfamily) gives rise to cells termed
as pre-NKP cells or ILCP (ILC precursors). Pre-NKP and ILCP cells are distinguished by
their loss/reduction of c-kit and FLT3 expression, along with their expression of the 2B4
receptor (CD244). The next stage in development is the NKP stage in the bone marrow,
which is classified by the expression of the IL-2 receptor and the lack of common NK
specific markers/ receptors.17
Next, the NKP develops into the iNK cell and finally the mNK cell through the
acquisition of these common NK markers. During the iNK stage, the cells gain the NK1.1
receptor, Nkp46 and TRAIL, while losing IL-7R. As NK cells mature, they lose
expression of CD27, while gaining markers involved in NK function such as integrin ⍺2
(CD49b, involved in cell adhesion), CD11b (also involved in cell adhesion), and the
Ly49 receptor.17
NK cell development is reliant on IL-15 expression, and IL-15 and IL-15R⍺
deficient mice lack circulating NK cells.18 This IL-15 is trans-presented by dendritic cells
(DCs). These DCs recognize type I IFN signals, which causes an upregulation of surface
IL-15 and IL-15R⍺, which are needed to allow for NK cell priming and development.19
Receptors
Murine NK cells possess a wide range of receptors that fit into multiple families.
Some of these receptor families are found on the mouse chromosome 6, specifically in
the NK gene complex (NKC). In this complex, a high degree of homology exists between
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members of the same family (up to 98% at the amino acid level), while this homology is
reduced to 20-30% between families.20
These receptors function in two ways based on the nature of the receptor. There
are activating and inhibitory receptors. Inhibitory receptors recognize self ligands.
Following this recognition, the target cells are spared due to the presence of selfrecognition. Often, inhibitory receptors of the Ly49 family of receptors recognize
classical MHC I molecules, while CD94/NKG2A receptors bind non-classical MHC I
molecules like Qa-1as self ligands.21
Inhibitory receptors rely primarily on signaling to immunoreceptor tyrosine-based
inhibition motifs (ITIMs). After the ligand binds to the inhibitory receptor, Src kinases
phosphorylate the ITIM, and the tyrosine residue is able to dock intracellular tyrosine
phosphatases SHP-1 and SHP-2 (src-homology containing protein tyrosine phosphate-1
and -2, respectively), bringing them close in proximity to the cell membrane.22 This
relocation inhibits NK cell cytotoxic activity as SHP-1 and SHP-2 dephosphorylate other
signaling molecules within the NK cell.22,23
NK cell activating receptors on the other hand typically do not express ITIMS, but
instead interact with immunoreceptor tyrosine activation motif (ITAM)- containing
adapter proteins FcɛRIγ, CD3ζ, and DAP12.22 Src family tyrosine kinases, including Lck,
Fyn and Src, phosphorylate the ITAMs on activating receptors, following the receptor’s
binding with its ligand.24 This results in the recruitment and activation of tyrosine kinases
Syk and Zap70, which engage downstream signaling pathways [including
phosphatidylinositol 3 kinase (PI3K), linker for the activation of T cells (LAT), and
mitogen-activated protein kinases (MAPKs)] resulting in an increase of intracellular
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calcium and cytoskeleton reorganization leading to the release of the NK cell’s cytotoxic
granules and the release of cytokines and chemokines by the NK cell.22,24
Following the engagement of activating and inhibitory receptors on the surface of
NK cells, the predominant signal will determine whether the NK cell’s cytolytic
functions will continue or come to a halt. The stronger signal between the activating and
inhibitory pathways determines the NK cell’s function and the target cell’s outcome. 25
The genes for three NK cell receptor families are present in the NKC on
chromosome 6. These include, (i) the Ly49 receptors, which recognize classical MHC-I,
(ii) the CD94/NKG family of receptors, which recognize non-classical MHC-I molecules
or MHC-I-like molecules, and (iii) the NKR-P1 receptor family, which recognize C-type
lectin-related (Clr) proteins. The NKR-P1:Clr receptor-ligand family is the focus of this
thesis.
NKR-P1 receptors
Among the receptor families of NK cells is the NKR-P1 family of cell surface
receptors, which are type II membrane glycoproteins of the C-type lectin-like family.
This family possesses both activating and inhibitory receptors. In mice, there are at least
six members of this multigene receptor family: Nkrp1a, Nkrp1c, Nkrp1d/Nkrp1b (alleles
of the same gene found in different mouse strains26), Nkrp1e, Nkrp1f and Nkrp1g.27 Each
of these genes code for one receptor, except Nkrp1e which is a pseudogene in B6 mice. 28
The ligands of this receptor family, belonging to the C-type lectin-related glycoprotein
family (Clr proteins), are encoded by genes which are interspersed among Nkrp1
genes,27,29,30 to preserve MHC-I-independent self-tolerance.22
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The first NK cell-specific protein identified in mice was NK1.1,31 later identified
as a member of the NKR-P1 family of receptors: NKR-P1C,32 an activating receptor.
This receptor possesses a charged intramembrane domain that associates with an adaptor
protein with an ITAM, FcεRIγ.33 The other identified activating receptors belonging to
this family, possessing the same charged domain, are NKR-P1A and NKR-P1F.34 The
inhibitory receptors, NKR-P1B/D and NKR-P1G, possess ITIMs which explain their
inhibitory nature.26,35
NKR-P1B receptor
NKR-P1B is an inhibitory receptor which interacts with Clr-b, a protein expressed
on the surface of many healthy self cells, as well as on the surface of some infected and
cancerous cells.36 This receptor is found to be expressed on approximately 60% of NK
cells in B6 mice, and plays an important role in MHC I-independent NK cell education.27
The axis of NKR-P1B:Clr-b (Figure 1) has been the focus of many studies aiming to
evaluate its effect on infected cell and cancer recognition by NK cells. It has been found
that Clr-b is downregulated through Ras oncogene overexpression in mouse fibroblasts
and leukemia cells37 and other tumours.36 Alternatively, there is evidence that some
cancers may selectively express Clr-b in order to escape NK cell immunosurveillance,36,38
while viral proteins may directly bind the NKR-P1B receptor to achieve the same
function.39 It has also been shown that the absence of the NKR-P1B receptor in knockout
mice with spontaneous myc-induced B cell lymphoma (maintaining Clr-b expression)
leads to slower tumour growth and progression.38
In humans, there is only one member of the NKR-P1 family, NKR-P1A,
expressed on the majority of human NK cells, and subsets of thymocytes and fetal T
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cells.40 The human NKR-P1A possesses 46% homology with mouse NKR-P1 receptors at
the amino acid level.40 It is an inhibitory receptor determined to bind lectin-like
transcript-1 (LLT-1), leading to the sparing of target cells.41 The murine NKR-P1B
receptor and its ligand is Clr-b, have been shown to be analogous to the human NKRP1A receptor and its LLT-1 ligand.22

Figure 1: Interaction between NKR-P1B and its cognate ligand, Clr-b.
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Education
NK cells are typically not activated by healthy host cells, and this prevents their
destruction due to the effects of the healthy cell’s inhibitory receptors. This signalling is
typically done through the use of MHC I molecules which act as ligands for the NK cell’s
inhibitory receptors. Traditionally, NK cells were thought to express at least one MHC I
specific inhibitory receptor to prevent self-reactivity and support the concept of missingself.42 More recently, however, it has been proposed that the NK cells (which exist in
healthy humans and mice) that do not express any inhibitory receptors exhibit a
hyporesponsive phenotype, through a “disarming” model due to their continued
stimulation.43 There is also an “arming” model which proposes that the priming of NK
cells is done after ligation is achieved through signalling of the MHC I specific inhibitory
receptors, which leads to functional maturation of the NK cells.42
NK cell education is typically marked by the expression of Ly49, the most
commonly studied MHC I-specific inhibitory receptor. Classical NK cell education
occurs when signalling through an inhibitory receptors occurs by using self MHC I
molecules, leading to responsive NK cells.44 Another method by which NK cells undergo
education is non-classical MHC I-dependent education. This is done through the
signalling of NK cell inhibitory receptors such as CD94/NKG2A by its non-classical
MHC I ligand, Qa-1.44 There is also a mechanism by which NK cells are able to mature
by signalling with inhibitory receptors that do not rely on MHC I molecules, as in the
case of NKR-P1B and its ligand Clr-b. NK cells that express NKR-P1B are more
responsive towards stimulation and display higher activity than those NK cells that do not
express NKR-P1B.27 This mechanism of education, which does not use classical or nonclassical MHC I ligands, is described as MHC I-independent NK cell education.
9

Missing-self
The missing-self hypothesis proposes the mechanism by which NK cells are able
to distinguish between healthy self cells and infected or foreign cells based on the
observation that NK cells were able to lyse target cells that expressed little to no type I
MHC molecules.45 This observation led to the proposal of the missing-self hypothesis
theory by Ljunggren and Karre,45 which attempted to explain the phenomenon by which
NK cells achieved their killing due to the loss of expression of molecules that indicated to
the NK cells that the target cells were those that were “healthy” and belonging to the
host’s body (Figure 2). This hypothesis was made prior to the discovery of inhibitory
receptors that recognized the type I MHC molecules and the discovery of the signalling
balance that is needed to activate NK cell effector function. At the time, it was concluded
that self MHC was required in order to protect the host’s cells from NK cells and allow
for their sparing. According to this theory, the loss of these self-molecules indicated to
the NK cells that these target cells were harmful to the host and should be exterminated.
Effector Function
NK cells initiate apoptotic pathways in their target cells leading to their death.
This is done through the degranulation of their lytic granules containing primarily
granzymes and perforin, creating a synapse with target cells. Perforin binds to the target
cell creating a pore complex, which mediates the entry of granzymes A and B into the
target cells.46–48 The granzymes induce DNA damage, and can do so independent of pore
complex formation by perforin.46,47 These proteins are translated post activation of the
NK cells.48 Resting murine NK cells are minimally cytotoxic due to a block of the
translation of the mRNA encoding these proteins.48
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Activation of the cells is reliant on the signalling to their receptors, which can be
inhibitory or activating and lead to the sparing or killing of the target cell. The inhibitory
receptors recognize self-ligands, leading to the sparing of the target cells, while the
activating receptors recognize foreign ligands, and lead to the death of the target cells
through apoptotic pathways.25 The balance between the two signals is what determines
the overall activation of the NK cell, and the fate of the target cell (Figure 2). Typically,
MHC I (class I major histocompatibility complex) I dependent inhibitory receptors are
able to illicit a stronger signal which outpowers the activation signals and inhibits NK
cell function.34
In infected cells and altered self cells, there is usually a loss of expression of selfligands,45 which limits the signalling of the inhibitory receptors and leads to target cell
death through the activating receptors (Figure 2). Cancer cells can also bind to the
inhibitory receptors, mimicking healthy host cells through the use of self-ligands, leading
to the inhibition of NK cell activity on cancer cells.

Healthy self
Inhibitory
receptor

Missing-self
Inhibitory
receptor

NK cell

NK cell

Activating
receptor

Activating
receptor

Normal
cell

Missingself cell

Ø Target cell is not killed

Ø Target cell is killed
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Figure 2: Signalling to NK cell activating and inhibitory receptors determines target cell
fate.
NK cells are also able to achieve their killing of foreign or infected cells through a
process named antibody-dependent cellular cytotoxicity (ADCC). This process depends
on the activity of the CD16 (FcγRII) receptor on the surface of NK cells. CD16 is an
activating receptor which binds antibodies, typically IgG, leading to a signal transduction
pathway that kills the targeted cell.49 Specifically, after an antibody binds a target cell,
the Fcγ receptor of NK cells recognizes the Fc (fragment crystallizable) region of the
antibody and induces a cross-linking between the receptor and antibody.50 This leads to
the release of the NK cells’ lytic granules and cytokine production, leading to the target
cell’s death.50
Finally, NK cells are able to lyse their targets through their signalling via death
receptors on the surface of target cells, using the NK surface tumour necrosis factor
(TNF)-related apoptosis-inducing ligands (TRAIL) or Fas ligands (FasL).47 TRAIL
functions by binding to death receptors DR4 and DR5 on the surface of (cancerous) target
cells and inducing apoptosis. TRAIL may also be used to identify iNK cells, as it is the
dominant mediator of NK cell cytotoxicity in earlier stages of NK cell development. 51 On
the other hand, FasL interacts with the Fas receptor and leads to apoptosis of the target
cell52, and its expression is typically limited to mNK cells.47
Immunosurveillance
Historically, NK cells have been assessed for their ability to eliminate tumour
cells due to their recognition of the transformed self cells. In the absence of NK cells, it
has been shown that cancers are able to grow more aggressively and have a poorer
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prognosis.53,54 This indicates that NK cells play an important role in the prevention of
tumour development due to their properties of immunosurveillance. This was also
dependent on the signaling molecules expressed by the cancers, which allowed for
recognition by the NK cells.
This immunosurveillance is not perfect, however. Cancers are able to evade NK
surveillance through their upregulation of self ligands that indicate to NK cells that they
are healthy self cells that are not altered. This way, NK cells are receiving an inhibitory
signal towards their killing, which can dominate the activating signal and prevent the
killing of the target cancer cells.
Breast Cancer
Cancer is currently a leading cause of premature deaths worldwide, 55 and breast
cancer contributed to the highest incidence of cancers worldwide in 2020 1 and among the
highest in previous years.2,3 Breast cancer is a heterogenous disease that appears to
resemble hematological cancers due to its lack of a dominant pathway of development
unlike other epithelial cancers.56 In such, breast cancer is classified based on distinctive
criteria allowing for enhanced diagnosis. Breast cancer may be categorized histologically
as in situ carcinoma or invasive carcinoma. In situ carcinoma is classified as ductal or
lobular carcinoma in situ57 (DCIS or LCIS, respectively), with DCIS being further
classified as cribriform, micropapillary, solid, papillary, and comedo.58 Otherwise,
invasive carcinomas are classified as “infiltrating ductal [IDC], invasive lobular,
ductal/lobular, mucinous (colloid), tubular, medullary and papillary carcinomas.”57 IDC
is the most prevalent of the invasive carcinomas,59 and can be classified into three grades
(1-3) based on differentiation (well, moderately, and poorly differentiated).60
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Molecular classification of breast cancer involves determining the gene
expression analysis and surface receptor analysis of breast cancer cells. This
classification is dependent on the expression of estrogen receptors (ER), progesterone
receptors (PR), and human epidermal growth factor receptor 2 (HER2).61 These
biomarkers are important for determining prognosis and treatment regimens for patients
with breast cancer.61
Current Breast Cancer Therapy
Breast cancer therapy consists of several ways of targeting the tumour cells and
can be categorized into surgery, drug therapy (chemotherapy, biological/targeted therapy,
and hormone therapy), radiation therapy, and immunotherapy. Surgery, used in cases of
nonmetastatic breast cancer, involves either a total mastectomy or the excision of the
tumour accompanied by radiation therapy.62 Chemotherapy is an option that can be used
in order to shrink the tumour prior to surgery (neoadjuvant chemotherapy) or postsurgery (adjuvant chemotherapy) or in the cases of high-risk patients that cannot undergo
surgery (systemic chemotherapy).63 Biological therapy is typically used in the treatment
of patients with HER2-positive breast cancer with the drug trastuzumab, a monoclonal
antibody that targets the HER2 receptor on the surface of cancer cells.63 Hormone
(endocrine) therapy is used in the treatment of HR-positive breast cancers and involves
the administration of drugs to prevent the production of hormones (especially estrogen)
or block the hormones’ interaction with cancer cells.64 Radiation therapy is typically used
as an adjuvant therapy to help eradicate the body of remaining cancer cells and prevent
reoccurrence of the disease. Immunotherapy as a treatment for cancers, including breast
cancer, has been a heavily researched area in recent years. Current immunotherapy
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regimens include the use of vaccines, immune checkpoint inhibition, adoptive cell
therapies, and oncolytic viruses.65
NK cells in cancer
NK cells are great contributors to the anti-tumour effects conducted by the
immune system against cancer cells, as they do not rely on a previous encounter in order
to produce their cytotoxic effects. Instead, NK cells, which contribute to <5% of tumourinfiltrating lymphocytes (TILs),66 are able to infiltrate solid tumours due to the activity of
their receptors that are able to recognize the tumour cells as altered self cells. High levels
of tumour infiltrating NK cells (TINKs) have been linked to a better prognosis in several
cancer types and in breast cancer higher densities of TINKs are linked to better overall
survival and disease-free survival rates in patients.67
Anti-tumour mechanisms
NK cells are linked to their ability to infiltrate tumours as a part of their host
defence mechanisms. NK cells recognize cancer cells through the use of their surface
receptors due to alterations of the surface ligands of the cancerous cells. Cancer cells
typically display a lower degree of inhibitory signals which tips the signalling balance in
favour of the activation signal, leading to the killing of the cancer cells by the NK cells,
without prior priming of the NK cell and acts as a part of the innate immune system.
Since NK cells do not require priming in order to achieve their killer function,
they are among the optimal cancer clearing effector cells of the immune system. In fact,
high levels of NK markers (increased NK cell density) in tumours of most solid tumourbearing mice contributed to a better prognosis.68 However, there are several limitations to
the NK cells’ anti-tumour activity. Among these are the changes initiated by tumour cells
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to reduce NK activity. These changes include the downregulation of the activating
receptors on the surface of NK cells such as NKG2D69 and NKp46,70 while also
decreasing the expression of IL-2, TNF-⍺, IFN-γ and leave NK cells in a state of low
cytotoxicity.70,71 Additionally, the tumour microenvironment (TME), consisting of cancer
cells and other host cells, is one that reduces NK cell anti-tumour activity.72 In this
microenvironment, there are immunosuppressive factors that reduce NK cell activity
directly, such as TGF-β, or by stimulating other immune cells to signal a reduction in NK
activity.72 TMEs also provide an environment for NK cells that is poor in nutrients and
other metabolic requirements needed by NK cells.72
NK cells, like other immune cells, may exhibit an exhausted phenotype when
exposed to tumours or chronic infections, characterized by poor effector function.73 NK
cells with decreased cytotoxic effects are implicated in a higher risk of cancer, 74 and
cancer progression appears to decrease TINK cytotoxicity through the decreased
expression of cytokines, granzyme B, perforin, and FasL/TRAIL.75–77 There are several
phenotypes associated with the exhaustion of NK cells. There appears to be a
downregulation of activating receptors NKG2D76,78 and CD1678, and increased
expression of the inhibitory receptor NKG2A77 in tumour-associated NK cells. PD-1, an
inhibitory receptor expressed by activated lymphocytes, also appears to be upregulated in
Kaposi sarcoma79 and other cancers,73 leading to impaired NK degranulation and
cytokine production.79,80 This phenotype is also associated with a downregulation in the
production of eomesodermin (EOMES) and T-bet, transcription factors involved in
developmental processes, implicated in the development of said exhausted phenotype
intrinsically.81
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Myeloid derived suppressor cells in cancer
Myeloid derived suppressor cells (MDSCs) are heterogenous myeloid cells,
present at various stages of differentiation and implicated in the suppression of the antitumour effects of immune cells.82,83 These cells are characterized by their co-expression
of myeloid lineage markers CD11b and Gr-1 (composed of Ly6C and Ly6G). In mice,
there are two subsets of MDSCs established: polymorphonuclear MDSCs (PMNMSDCs), which are CD11b+Ly6ClowLy6G+, and mononuclear MDSCs (M-MDSCs),
which are CD11b+Ly6ChighLy6G−.84 These subsets employ different mechanisms by
which they can suppress immune function in disease, with PMN-MDSCs appearing to
have a higher prevalence across different cancer types.85 MDSCs seemingly rely on the
upregulation of granulocyte colony stimulating factor (G-CSF), granulocyte macrophageCSF (GM-CSF) and macrophage-CSF (M-CSF) present in the TME,86 coupled with other
proinflammatory cytokines such as IL-4 and IL-6.87 The coupling of these two signals is
required to allow for the expansion of immature myeloid cells and inducing the
suppressive phenotype exhibited by MDSCs, respectively.88
MDSCs are implicated in less favourable cancer prognoses when expressed in
high levels in the peripheral blood and in circulation. 89,90 M-MDSCs prevalence is also a
measure of breast cancer metastasis.91 M-MDSCs are able suppress immune function
non-specifically through their release of immunosuppressive cytokines, nitric oxide and
arginase 1.92 In breast cancer, it has been shown that γδ T cells produce IL-17 which
stimulate PMN-MDSCs leading to the inhibition of CD8+ T cells,93 and that PMNMDSCs reduced NK cell cytotoxicity.94
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Knowledge gap
Previously, NKR-P1B has been linked to the regulation of cancer immune responses
against myc-induced B cell lymphoma.38 Clr-b, the ligand for NKR-P1B receptor, was
found to aid cancer cells in NK cell immunoevasion in NKR-P1B-sufficient mice, and
NKR-P1B-deficient mice were found to be more resistant to myc-induced B cell
lymphoma development.38 Additionally, in vitro and in vivo data demonstrate the role of
NK cells in the control of E0771 mammary adenocarcinoma cells,95 which was found to
express Clr-b. It is not known the extent by which NKR-P1B is able to regulate the
cancer immune response against solid tumours, namely E0771 mammary
adenocarcinoma-induced tumours.

18

HYPOTHESIS AND RESEARCH OBJECTIVES
Based on previous findings, we aimed to determine the role of NKR-P1B in E0771
mammary adenocarcinoma-induced tumour immunosurveillance and NK cell-mediated
lysis of the cancer cells. We hypothesize that the NKR-P1B:Clr-b axis plays an important
role in solid tumour immunosurveillance (such as mammary tumours) in mice, and that
the blockade of this axis will lead to earlier tumour detection by NK cells and increased
NK cytotoxic activity.
In this project, we aim to assess the role of the NKR-P1B:Clr-b axis in E0771 mammary
adenocarcinoma-induced tumour immunosurveillance. Specifically, NK cells from NKRP1B-deficient mice will be compared to those from WT B6 mice in the detection and
clearance of WT E0771 mammary adenocarcinoma-induced tumours and E0771 Clr-b-/(KO)-induced tumours. This will be done by analyzing tumour growth in the two mice
strains and looking at the expression of transcription factors, activation markers, surface
receptors, immune checkpoint receptors and differentiation markers of tumour-infiltrating
NK cells. Additionally, tumour-infiltrating NK cells from tumour-bearing mice will be
stimulated in vitro to assess functional differences.
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MATERIALS AND METHODS
Mouse models
C57BL/6 (B6) mice were acquired from the Jackson Laboratory. NKR-P1B deficient
mice were previously generated on a B6 background (NKR-P1BB6-deficient) by Rahim et
al.38
Cell lines
E0771 mammary adenocarcinoma cells originate from a spontaneously arising medullary
breast adenocarcinoma in a B6 mouse.96 YAC-1 is a mouse lymphoma that is induced by
the inoculation of A/Sn (A/JSnYCit) mice with the Moloney leukemia virus,10 used to
examine NK cytotoxic activity. Both cell lines were kindly provided by Dr. Makrigiannis
at Dalhousie University.
E0771 Clr-b-/- cells were generated and provided by Raghd Al-Olabi, a fellow graduate
student in our lab, using the CRISPR-Cas9 system. E0771 and E0771 Clr-b-/- cells were
cultured in DMEM supplemented with 10% fetal bovine serum (FBS) and 1% penicillinstreptomycin (P/S) and harvested with 0.25% trypsin-EDTA. YAC-1 cells were cultured
in RPMI-1640 supplemented with 10% FBS and 1% P/S. All cells were incubated at
37°C with 5% CO2.
Mammary fat pad injection
WT and NKR-P1B deficient B6 mice were injected with 5*104 E0771 or E0771 Clr-b-/cells in the mammary fat pad. Mice were first anesthetized with 2.5% isoflurane gas in 1
L/min oxygen for 2-3 minutes. The adenocarcinoma cells suspended in 100 µL sterile
PBS were injected into the 4th mammary gland fat pad using a 28G insulin syringe
(Becton Dickinson). Mice were examined semi-weekly post-injection for palpable
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tumours and tumour measurements were obtained using a digital caliper. Tumour size
was recorded as the average of two separate tumour diameter measurements. Mice were
euthanized when tumour diameter exceeded 1 cm, and tumours and spleens harvested and
dissected for analysis and stimulation.
Splenocyte and tumour cell extraction
Mice which were at end point were euthanized, with their tumours and spleens extracted
for analysis and further stimulation.
Spleens were extracted from the mice and dissociated by crushing them between two
microscope slides in phosphate buffered saline (PBS). Red blood cells were then lysed
using an ACK (Ammonium-Chloride-Potassium) lysis buffer for 3 minutes and the
solution was neutralized using 10 mL PBS to retrieve splenocytes to be used in the
experiments.
Tumours were chopped using a razor blade into small pieces and incubated for 30 min at
37°C in 5 mL digestion media (containing 5 mL serum-free DMEM + 200 µg/mL
collagenase D + 20 µg/mL DNAse 1). Digestion was halted by adding EDTA (1 mM) to
each tumour. Tumours were passed through a 70 µm cell strainer and washed with 10 mL
PBS-EDTA (PBS + 1 mM EDTA) to attain single-cell suspensions. Red blood cells were
lysed using the ACK lysis buffer for 3 minutes and the solutions were neutralized with
PBS.
Both splenocytes and tumours cells were suspended in PBS and counted using a
hemocytometer and adjusted to concentrations needed for further analyses.
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In vitro stimulation of NK cells
1*106 mouse splenocytes and tumour cells were suspended in 100 µL complex RPMI1640 (containing 10% FBS, 1% P/S, 1% HEPES, 1% non-essential amino acids, 1%
sodium pyruvate, 0.5% 2-mercaptoethanol). Cell suspensions were plated in a 96-well
round-bottom plate with 0.2 µL brefeldin A (BFA), 0.2 µL monensin (MNS), and 0.5 µL
anti-CD107a-FITC antibody. Cells were left combined with their stimulations:
unstimulated (with 100 µL complex RMPI) or stimulated with PMA and ionomycin (100
µL complex RPMI + 20ng/mL PMA + 1 µg/mL ionomycin), IL-12 + IL-18 (100 µL
complex RPMI + 10 ng/mL IL-12 + 10 ng/mL IL-18), or YAC-1 (2*105 cells in 100 µL
complex RPMI). The plate was then incubated for 4 hours at 37°C before being spun at
500XG for 5 min. Supernatant was discarded and cells were stained extracellularly in a
suspension of anti-CD45-AF700, anti-NK1.1-PE-594 and anti-TCRβ-BV510 at a ratio of
1:200 in 50 µL FACS buffer. Following suspension, cells were incubated for 20-30
minutes in the dark at 4°C. Cells were then washed with 150 µL FACS buffer and spun at
500XG for 5 min. Cells were then suspended in 100 µL fixation buffer and incubated in
the dark at 4°C. Cells were washed with 100 µL permeabilization buffer and spun at
500XG for 5 min. The cells were then washed with 200 µL permeabilization buffer and
spun again. Intracellular staining using EOMES-APC, and IFNγ-PE at a ratio of 1:200
was done in 50 µL permeabilization buffer for 20-30 mins in the dark, at 4°C. Cells were
washed with 150 µL permeabilization buffer, spun and resuspended in 400 µL FACS
buffer to be acquired.
Flow cytometry data was acquired using a BD LSR Fortessa™ X-20 analyzer using the
BD FACSDiva™ software and analyzed using FlowJo™ software.
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Tumour analysis
1*106 splenocytes and tumour cells were suspended in different stain mixtures outlined in
tables 1-10 using different antibodies to observe the different NK cell phenotypes.
Staining was performed as described above, without in vitro stimulation.
Stain 1:
Table 1: Stain 1 – Surface stain, primary antibodies
Antibody

Colour

Ratio

CD45

AF700

1:300

NK1.1

PE-594

1:100

TCRβ

BV510

1:200

CD49a

PE

1:100

CD49b

PE-Cy7

1:100

Ly49C/IBiotin
FVD

N/A

1:300

APC-Cy7

1:500

Table 2: Stain 1 – Surface stain, secondary antibodies
Antibody

Colour

Ratio

Streptavidin

PerCP Cy5.5

1:300

Table 3: Stain 1 – Intracellular antibodies
Antibody

Colour

Ratio

EOMES

APC

1:200

Ki67

FITC

1:200

Granzyme-B

BV421

1:500
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Stain 2:
Table 4: Stain 2 – Surface antibodies
Antibody

Colour

Ratio

CD45

AF700

1:300

NK1.1

PE-594

1:100

TCRβ

BV510

1:200

CD27

FITC

1:100

CD11b

PerCP Cy5.5

1:100

KLR-G-1

PE

1:100

NKp46

BV421

1:50

FVD

APC-Cy7

1:500

Table 5: Stain 2 – Intracellular antibody
Antibody

Colour

Ratio

EOMES

APC

1:200

Stain 3:
Table 6: Stain 3 – Surface antibodies
Antibody

Colour

Ratio

CD45

AF700

1:300

NK1.1

PE-594

1:100

TCRβ

BV510

1:200

PD-1

FITC

1:100

DNAM1

PerCP Cy5.5

1:100

NKG2D

PE

1:100

TIGIT

BV421

1:100

FVD

APC-Cy7

1:500
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Table 7: Stain 3 – Intracellular antibody
Antibody

Colour

Ratio

EOMES

APC

1:200

Stain 4:
Table 8: Stain 4 – Primary antibodies
Antibody

Colour

Ratio

CD45

AF700

1:300

Gr-1

FITC

1:100

CD11b

PerCP Cy5.5

1:100

4A6 (Clr-b)

N/A

1:400

FVD

APC-Cy7

1:500

Table 9: Stain 4 – Secondary antibody
Antibody

Colour

Ratio

Anti-rat IgM

PE

1:200

Table 10: Stain 4 – Secondary antibody alone control
Antibody

Colour

Ratio

CD45

AF700

1:300

Gr-1

FITC

1:100

CD11b

PerCP Cy5.5

1:100

FVD

APC-Cy7

1:500

Statistical analyses
Statistical analyses were performed using GraphPad Prism software. Statistical
significance was determined using a two-tailed student T-test and ANOVA tests with a
cut-off P value of 0.05 [P<0.05(*), P<0.01(**), P<0.001(***)]. Significance is denoted
on the graphs.
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RESULTS
Disrupting the NKR-P1B:Clr-b axis delays tumour growth
To evaluate the effects of the NKR-P1B receptor and its cognate Clr-b ligand in
breast cancer immunosurveillance, female WT (B6) and Nkrp1b-/- mice were injected in
the mammary fat pad with E0771 (WT tumour) and E0771 Clr-b-/- (KO tumour) cells.
Tumour diameter was measured to determine the effects of the NKR-P1b:Clr-b
interactions on the tumour growth rate. In mice injected with WT E0771 cells, which
express Clr-b, fewer Nkrp1b-/- mice developed tumours compared to their WT mouse
counterparts (Figure 3A). In addition, in two Nkrp1b-/- mice, but none of the WT mice,
the tumours resolved spontaneously, which were undetectable after the 35-day mark postinjection (Figure 3A). In some Nkrp1b-/- mice, tumours did not grow at all after detection
(data not shown). This data demonstrates that NKR-P1B receptor plays a role in
mammary tumour immunosurveillance, and NKR-P1B-deficient mice are more resistant
to mammary tumour induction by E0771 cells.
In mice injected with Clr-b-KO E0771 tumour cells, both WT and Nkrp1b-/- mice
show similar tumour growth (Figure 3B). Clr-b-deficiency does not appear to affect
tumour growth in WT mice, however, Nkrp1b-/- mice are less resistant to Clr-b-KO
E0771 tumours compared to WT E0771 tumours. This could be due to the impaired
missing-self response by NK cells from Nkrp1b-/- mice, where NKR-P1B-deficient NK
cells are unable to detect and respond against Clr-b-deficient target cells.38 The data in
Figure 3 demonstrates that the role of the NKR-P1B receptor in mammary tumour
immunosurveillance is dependent on the expression of its cognate Clr-b ligand on tumour
cells.
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Figure 3: Nkrp1b-/- mice develop tumours slower than WT counterparts.
A, palpable mammary tumours were measured weekly in female WT mice (black lines,
n=11) and Nkrp1b-/- mice (orange lines, n=5) injected with E0771 tumour cells. Each line
represents a single tumour in a single mouse. B, palpable mammary tumour size was
measured weekly in female WT mice (black lines, n=12) and Nkrp1b-/- mice (red lines,
n=7) injected with E0771 Clr-b-/- tumour cells. Each line represents a single tumour in a
single mouse.
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NKR-P1B:Clr-b axis disruption effects EOMES+ NK cell tumour infiltration
To determine the immunological basis for the apparent role of NKR-P1B:Clr-b
interactions in mammary tumour immunosurveillance, we performed flow cytometry
analysis on NK cells in tumour-infiltrating lymphocytes (TIL) and splenocytes from WT
and Nkrp1b-/- mice injected with WT and Clr-b-KO E0771 tumour cells. TILs and
splenocytes were stained using antibodies against various cell surface and intracellular
markers to determine the frequency and phenotype of NK cells.
The expression of eomesodermin (EOMES), a T-box transcription factor is
required for NK cell maturation. Traditionally, EOMES is used to distinguish EOMES+
NK cells from EOMES- ILC1 cells; however, the loss of EOMES expression is also
linked to immunological “exhaustion” and diminished anti-tumour responses.73,97 Both
the EOMES+ and EOMES- subsets of NK cells (identified as CD45+NK1.1+TCRb-) can
be detected in the spleen and tumours (Figure 4A). In mice bearing WT E0771 tumours,
no major differences were observed in the proportions of EOMES+ and EOMES- NK
cell subsets between WT and Nkrp1b-/- mice (Figure 4B). However, in E0771 Clr-b-/tumours, there was a decrease in the proportion of EOMES+ and a corresponding
increase in EOMES- NK cells in Nkrp1b-/- mice compared to the WT mice (Figure 4D).
Conversely, there was an increased proportion of EOMES+ and a decreased proportion of
EOMES- NK cell subsets in the spleens from E0771-Clr-b-/- tumour-bearing KO mice
compared to the WT mice (Figure 4E). These differences were not statistically
significant possibly due to low sample numbers. No difference is apparent in the
proportion of EOMES+ and EOMES- NK cells in the spleens of WT and KO mice
injected with the WT E0771 tumour cells (Figure 4C).
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Together, the data shows there is a loss of EOMES expression in a larger
proportion of Nkrp1b-/- tumour-infiltrating NK cells compared to the WT NK cells in Clrb-deficient tumours, which could have an impact on their effector functions.
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Figure 4: NKR-P1B:Clr-b axis disruption effects EOMES+ NK cell tumour infiltration.
A, gating strategy for EOMES+ and EOMES- subsets: gating was done as
CD45+NK1.1+TCRβ-EOMES+ and CD45+NK1.1+TCRβ-EOMES-. B and C, graphical
representation of mean EOMES+ and EOMES- NK cell percentages in the tumours (B)
and spleen (C) of WT and Nkrp1b-/- mice injected with WT E0771 tumours (n=7 and
n=1, respectively). D and E, graphical representation of mean EOMES+ and EOMESNK cell percentages in the tumours (D) and spleen (E) of WT and Nkrp1b-/- mice injected
with Clr-b KO E0771tumours (n=9 and n=4, respectively).
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Nkrp1b-/- NK cells exhibit reduced proliferative capacity in tumours
To assess the activation status of tumour-infiltrating NK (TINK) cells, Granzyme
B and Ki67 expression levels were determined in both EOMES+ and EOMES- subsets.
Granzyme B is one of the cytotoxic effector molecules released by activated NK cells. Its
expression is increased in activated NK cells. The expression of Ki67, a nuclear protein
involved in cell proliferation, is increased in activated NK cells undergoing proliferation.
No differences in granzyme B expression level were observed in tumour-infiltrating
EOMES+ and EOMES- NK cells subsets between WT and Nkrp1b-/- mice (Figure 5).
However, there was a marked decrease in Ki67 expression in both the EOMES+ and
EOMES- NK cells in the Nkrp1b-/- mice compared to the WT mice bearing either the WT
E0771 tumours (Figures 6B and C) or E0771-Clr-b-/- tumours (Figures 6D and E). The
lower NK cell proliferation in Nkrp1b-/- mice correlates with the greater loss of EOMES
expression in NK cells from Nkrp1b-/- mice bearing EOMES-Clr-b-/- tumours. This could
also reflect the lower tumour burden, and by extension lesser NK cell proliferation in the
Nkrp1b-/- mice bearing E0771 tumours.
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Figure 5: Granzyme B production by TINK cells from WT and Nkrp1b-/- mice.
A, gating strategy among EOMES+ and EOMES- subsets: gating was done as
CD45+NK1.1+TCRβ-EOMES+ and CD45+NK1.1+TCRβ-EOMES- cells for Granzyme B
production. B and C, graphical representation of mean Granzyme B production by
EOMES+ (B) and EOMES- (C) TINK cells of WT (n=7) and Nkrp1b-/- (n=1) mice
injected with WT tumours. D and E, graphical representation of mean Granzyme B
production by EOMES+ (D) and EOMES- (E) TINK cells of WT (n=9) and Nkrp1b-/(n=4) mice injected with Clr-b KO tumours.
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A

Figure 6: Reduced Ki67 expression by TINK cells from Nkrp1b-/- mice.
A, gating strategy among EOMES+ and EOMES- subsets: gating was done as
CD45+NK1.1+TCRβ-EOMES+ and CD45+NK1.1+TCRβ-EOMES- cells for Ki67
expression. B and C, graphical representation of mean Ki67 expression by EOMES+ (B)
and EOMES- (C) TINK cells of WT (n=7) and Nkrp1b-/- (n=1) mice injected with WT
tumours. D and E, graphical representation of mean Ki67 expression by EOMES+ (D)
and EOMES- (E) TINK cells of WT (n=9) and Nkrp1b-/- (n=4) mice injected with Clr-b
KO tumours.
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Altered NK cell phenotype in mammary tumour-bearing Nkrp1b-/- and WT mice
Changes in NK cell phenotype has been shown during anti-tumour immune
responses and NK cell exhaustion. To determine the phenotype of NK cells in mice
bearing mammary tumours, we assessed the expression of several NK cell receptors,
adhesion molecules, and markers associated with immunological exhaustion. These
include activation receptors NKp46, NKG2D and DNAM-1, cell surface integrins CD49a
and CD49b, inhibitory receptors Ly49C/I, KLRG-1, and PD-1, and markers associated
with NK cell differentiation, CD27 and CD11b.
Amongst the activation markers, Nkp46 belongs to the family of natural
cytotoxicity receptors (NCRs),98 and is linked to recognizing and preventing metastasis in
various cancers.99 NKG2D is encoded by the NKC in mice, and is shown to play a role in
cancer immunosurveillance. DNAM-1 is a cell surface glycoprotein that functions as an
adhesion molecule which synergizes with activating receptors and triggers NK cell
cytotoxicity. No statistically significant difference in the proportion of the Nkp46+ NK
cells from tumour-bearing WT and Nkrp1b-/- mice was seen (Figure 7). However,
DNAM-1 appears to be expressed on larger percentage of NK cells from NKrp1b-/- mice
(Figures 7B-D) compared to WT mice regardless of the tumour type. NKG2D appears to
be expressed in greater proportion of NKrp1b-/- NK cells (n=1) compared to WT NK cells
in WT E0771 tumours (Figure 8C). However, the differences were not statistically
significant at this sample size.
Ly49C/I is an inhibitory receptor for class I major histocompatibility complex
(MHC-I), shown to place a role in mammary tumour immunosurveillance in mice.
Although we see a decrease in expression of this receptor in Nkrp1b-/- compared to WT
NK cells, this difference did not approach statistical significance (Figure 9).
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KLR-G-1 is a co-inhibitory receptor expressed by T cell and NK cells whose
inhibition has been linked to better immune responses in cancers.100 PD-1 (programmed
cell death protein 1) is involved in regulation of immune responses, and functions in
aiding tumour cells in immunoevasion from effector cells. KLRG-1 and PD-1 expression
is associated with immune exhaustion phenotypes. We observed an increased proportion
of EOMES- TINK cells in Nkrp1b-/- mice expressing PD-1 (Figure 10C) and KLRG-1
(Figure 10E) in the E0771 and E0771-Clr-b-/- tumours, respectively, compared to their
WT counterparts (Figure 10). This indicates that the EOMES- NK cells in mammary
tumours exhibit immune exhaustion phenotype, found to be elevated in NKR-P1Bdeficient mice. Expression of KLRG-1 and PD-1 is similar in EOMES+ NK cells
between WT and Nkrp1b-/- mice (Figures 10B and D).
CD49a (integrin α1β1) and CD49b/DX5 (integrin 2β1), cell-surface integrins, are
expressed on subsets of ILC1s and NK cells. Tissue resident NK cells typically express
CD49a, while NK cells which reside in lymphoid organs or found in circulation express
CD49b. CD49a+ TINK cell accumulation has been previously associated with exhausted
NK cell phenotypes, linked to poor cancer prognosis.101 CD49b is a marker for NK cell
maturation, and NK cells with low expression of this integrin exhibit much lower
cytotoxic function.102 The proportion of CD49a+ an CD49b+ TINK cells is largely
unaffected in WT and Nkrp1b-/- mice (Figures 11 and 12), however, there may be an
increased proportion of CD49a+ cells amongst the EOMES- TINK cells in WT E0771
tumours from Nkrp1b-/- mice (n=1) compared to WT mice (Figure 11C).
Finally, we compared markers associated with NK cell differentiation in WT and
Nkrp1b-/- mice bearing E0771 mammary tumours. The stages of maturation of NK cells
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are reliant on the expression of CD27 and CD11b. CD27 SP (CD27+CD11b-) NK cells
represent a more immature subset, while DP (CD27+CD11b+) NK cells are more mature,
followed by CD11b SP (CD27-CD11b+) NK cells. NK cell activation also induces
differentiation into a more mature CD27-CD11b+ phenotype. CD11b DP NK cells and
CD11b SP NK cells have been previously determined to show the highest potential for
cytokine production, while CD11b SP NK cells displayed the highest cytolytic
function.103 These subsets of tumour-infiltration NK cells were determined in the tumours
from WT and Nkrp1b-/- mice injected with both WT and Clr-b KO E0771 tumour cells.
In the mice bearing WT E0771 tumours, the Nkrp1b-/- mice displayed lower frequency of
CD11b SP NK cells and higher levels of CD27 SP and DP NK cells in comparison to
their WT counterparts in both EOMES+ and EOMES- NK cells subsets, indicating a
more immature phenotype (Figure 13B). Conversely, in mice bearing Clr-b KO tumours,
it is evident that Nkrp1b-/- mice possessed slightly elevated percentages of CD11b SP NK
cells, accompanied by a reduction in DP and an increase in CD27 SP NK cell percentages
when compared to their WT counterparts (Figure 13D).
The data together shows evidence of increased NK cell exhaustion (KLRG-1 and
PD1 expression) and lower NK cell proliferation in Nkrp1b-/- mice compared to the WT
mice, and differential expression of immune receptors and maturation markers depending
on the status of Clr-b ligand expression on the tumour cells.
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A

A

A

Figure 7: Activating receptor expression in WT and Nkrp1b-/- mice.
A, gating strategy among EOMES+ and EOMES- subsets: gating was done as
CD45+NK1.1+TCRβ-EOMES+ and CD45+NK1.1+TCRβ-EOMES- cells for the respective
activating receptors. B and C, graphical representation of mean Nkp46 and DNAM-1
expression on the surface of EOMES+ (B) and EOMES- (C) TINK cells of WT (n=7)
and Nkrp1b-/- (n=1) mice injected with WT tumours. D and E, graphical representation
of mean Nkp46 and DNAM-1 expression on the surface of EOMES+ (D) and EOMES(E) TINK cells of WT (n=8) and Nkrp1b-/- (n=4) mice injected with Clr-b KO tumours.
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Figure 8: NKG2D expression in WT and Nkrp1b-/- mice.
A and B, graphical representation of mean NKG2D expression on the surface of
EOMES+ (A) and EOMES- (B) TINK cells of WT (n=3) and Nkrp1b-/- (n=1) mice
injected with WT tumours. C and D, graphical representation of mean NKG2D
expression on the surface of EOMES+ (C) and EOMES- (D) TINK cells of WT (n=6)
and Nkrp1b-/- (n=4) mice injected with Clr-b KO tumours.
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Figure 9: Decreased Ly49C/I expression in

WT

Nkrp1b-/-

Nkrp1b-/-

mice.

A, gating strategy among EOMES+ and EOMES- subsets: gating was done as
CD45+NK1.1+TCRβ-EOMES+ and CD45+NK1.1+TCRβ-EOMES- cells for Ly49C/I
expression. B and C, graphical representation of mean Ly49C/I expression on the surface
of EOMES+ (B) and EOMES- (C) TINK cells of WT (n=5) and Nkrp1b-/- (n=1) mice
injected with WT tumours. D and E, graphical representation of mean Ly49C/I
expression on the surface of EOMES+ (D) and EOMES- (E) TINK cells of WT (n=7)
and Nkrp1b-/- (n=4) mice injected with Clr-b KO tumours.
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Figure 10: Markers of immune exhaustion in WT and Nkrp1b-/- mice.
A, gating strategy among EOMES+ and EOMES- subsets: gating was done as
CD45+NK1.1+TCRβ-EOMES+ and CD45+NK1.1+TCRβ-EOMES- cells for markers of
immune exhaustion phenotypes. B and C, graphical representation of mean KLR-G-1
and PD-1 expression on the surface of EOMES+ (B) and EOMES- (C) TINK cells of WT
(n=7) and Nkrp1b-/- (n=1) mice injected with WT tumours. D and E, graphical
representation of mean KLR-G-1 and PD-1 expression on the surface of EOMES+ (D)
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and EOMES- (E) TINK cells of WT (n=8) and Nkrp1b-/- (n=4) mice injected with KO
tumours.
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Figure 11: Increased CD49a expression in Nkrp1b-/- mice.
A, gating strategy among EOMES+ and EOMES- subsets: gating was done as
CD45+NK1.1+TCRβ-EOMES+ and CD45+NK1.1+TCRβ-EOMES- cells for CD49a or
CD49b expression. B and C, graphical representation of mean CD49a expression on the
surface of EOMES+ (B) and EOMES- (C) TINK cells of WT (n=7) and Nkrp1b-/- (n=1)
mice injected with WT tumours. D and E, graphical representation of mean CD49a on
the surface of EOMES+ (D) and EOMES- (E) TINK cells of WT (n=9) and Nkrp1b-/(n=4) mice injected with Clr-b KO tumours.
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Figure 12: Proportions of CD49b+ and CD49a- cells in tumour-bearing mice.
A and C, graphical representation of mean CD49b expression on the surface of EOMES+
TINK cells of WT (n=7) and Nkrp1b-/- (n=1) mice injected with WT tumours (A) and
WT (n=9) and Nkrp1b-/- (n=4) mice injected with KO tumours (C). B and D, graphical
representation of mean CD49a- frequency on the surface of EOMES- TINK cells of WT
(n=7) and Nkrp1b-/- (n=1) mice injected with WT tumours (B) and WT (n=9) and
Nkrp1b-/- (n=4) mice injected with Clr-b KO tumours (D).
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Figure 13: Maturation phenotype of TINK cells is altered in Nkrp1b-/- mice.
A, gating strategy among EOMES+ and EOMES- subsets: gating was done as
CD45+NK1.1+TCRβ-EOMES+ and CD45+NK1.1+TCRβ-EOMES- cells for CD27 and
CD11b expression. B and C, graphical representation of mean CD27 and CD11b coexpression on the surface of EOMES+ (B) and EOMES- (C) TINK cells of WT (n=7)
and Nkrp1b-/- (n=1) mice injected with WT tumours. D and E, graphical representation
of mean CD27 and CD11b co-expression on the surface of EOMES+ (D) and EOMES44

(E) TINK cells of WT (n=8) and Nkrp1b-/- (n=4) mice injected with Clr-b KO tumours.
DP cells are CD27+CD11b+.

45

MDSCs in mammary tumours express Clr-b
In addition to the tumour cells, Clr-b expression on other cells in the tumour
microenvironment can potentially interact with the NKR-P1B receptor to regulate NK
cell activity. Clr-b is expressed on all cells of hematopoietic origin. One such cell type
with immunosuppressive activity in tumours is myeloid-derived suppressor cells
(MDSC), however, it is not known if MDSCs express of Clr-b and can suppress NK cell
activity by engaging the NKR-P1B receptor. Heightened MDSC levels are linked to a
less favourable prognosis in various cancers.89,90 MDSC are prevalent in E0771
mammary tumours and constitute up to 40% of tumour-infiltration leukocytes. We
assessed expression of Clr-b in MDSCs and the frequency of these cells in tumourbearing WT and Nkrp1b-/- mice. Our data shows no significant differences in the
frequency of MDSC (CD45+CD11b+GR-1+) in the spleen or tumours from WT and
Nkrp1b-/- mice (Figures 14C-F), however, there is a trend towards increased MDSC
frequency in the spleens Nkrp1b-/- mice bearing Clr-b-KO tumours (Figure 14E).
Additionally, we show that MDSCs express Clr-b (Figure 14G), therefore, they could
potentially inhibit NK cell activity in tumours via the NKR-P1B receptor, even in
tumours which lack Clr-b expression in the tumour cells. Further experiments are needed
to confirm the role of NKR-P1B:Clr-b interactions in regulation of NK cells by MDSCs
in mammary tumours.

46

C D
Spleen
MDSC
(WT tumor)
Tumor
MDSC
(WT tumor)
1.5

% cells CD11b+ Gr-1+

1.5

1.0

0.5

1.0

0.5

0.0

0.0

20
10

WT Nkrp1b-/-

WT Nkrp1b -/-

FG
MDSC (KO tumor)

1.0

0.5

1.0

0.5

40
30
20
10

WT Nkrp1b -/-

2° alone antibody
Clr-b antibody
Tumor MDSC (KO tumor)

% cells CD11b+ Gr-1+

50

WT Nkrp1b-/-

40
30
20
10

Figure0 14: MDSC -/-prevalence in spleens and tumours of tumour-bearing mice.
WT Nkrp1b
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WT and Nkrp1b-/- mice. Gating on MDSC population, defined as CD11b+ Gr-1+ cells.
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CD107a and IFNγ production by splenic and tumour-infiltrating NK cells
Ex vivo analysis of tumour-infiltrating NK cells demonstrated evidence for NK
cell exhaustion characterized by loss of EOMES expression, reduced proliferation, and
expression of KLRG-1 and PD-1, notably more in the Nkrp1b-/- mice. To determine if
additional stimuli could restore NK cell functionality, we performed in vitro stimulation
of splenic and tumour-infiltrating NK cells, and quantified degranulation (by assessing
CD107a surface expression) and IFNγ production. CD107a, lysosome-associated
membrane protein 1 (LAMP-1), is a glycoprotein associated with the endosomal
compartment. Degranulation of NK cells result in transport of CD107a to the cell surface,
which can be detected by antibody staining and flow cytometry analysis. IFNγ, a
proinflammatory cytokine, is produced and released by activated NK cells.
When splenic NK cells from tumour-bearing mice were stimulated with PMA and
ionomycin, and YAC-1 target cells, EOMES+ NK cells demonstrated significant
degranulative activity (CD107a expression) (Figures 15 B and D). EOMES- NK cells
exhibited high baseline CD107a expression, consistent with them being activated cells,
but their degranulation was not further increased by in vitro stimulation (Figures 15C
and E). EOMES+ NK cells from Nkrp1b-/- mice demonstrated slightly lower
degranulation upon stimulation, however, the difference did not reach statistical
significance (Figures 15B and D). Similarly, greater proportions of splenic EOMES+
NK cells could be induced to produce IFNγ by PMA and ionomycin, and IL-12 plus IL18 stimulation than the EOMES- NK cells in both WT E0771 and Clr-b KO E0771
tumour-bearing mice (Figure 16).
Stimulation of tumour-infiltrating NK cells showed that, similar to splenic NK
cells, EOMES+ NK cells are more responsive to external stimuli in that they can be
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induced to degranulate and produce IFNγ more than EOMES- NK cells (Figures 17 and
18). Additionally, EOMES- tumour NK cells from Nkrp1b-/- mice were less responsive to
stimulation with PMA and ionomycin and exhibit lower degranulation compared to WT
mice (Figures 17B and D), consistent with the higher NK cell exhaustion phenotype
observed in tumours from the Nkrp1b-/- mice. Increased IFNγ+ NK cell percentage was
induced by stimulation of tumour-infiltrating leukocytes from Nkrp1b-/- mice bearing WT
tumour (n=1) compared to the WT mice.
Together, the in vitro stimulation data demonstrates that the EOMES- NK cell
subset in both the E0771 and E0771-Clrb-/- tumours have an activated phenotype
(CD107a+) and cannot be induce to further degranulate or produce IFNγ to the same
level as the EOMES+ NK cells.
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Figure 15: CD107a expression by splenic NK cells from tumour-bearing mice.
A, gating strategy among EOMES+ and EOMES- subsets: gating was done as
CD45+NK1.1+TCRβ-EOMES+ and CD45+NK1.1+TCRβ-EOMES- cells for CD107a and
IFNγ expression. B and C, graphical representation of mean CD107a production by
splenic EOMES+ (B) and EOMES- (C) NK cells of WT (n=9) and Nkrp1b-/- (n=2) mice
injected with WT tumours. D and E, graphical representation of mean CD107a
production by splenic EOMES+ (D) and EOMES- (E) NK cells of WT (n=10) and
Nkrp1b-/- (n=5) mice injected with Clr-b KO tumours.
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Figure 16: IFNγ production by splenic NK cells from tumour-bearing mice.
A and B, graphical representation of mean IFNγ production by splenic EOMES+ (A) and
EOMES- (B) NK cells of WT (n=9) and Nkrp1b-/- (n=2) mice injected with WT tumours.
C and D, graphical representation of mean IFNγ production by splenic EOMES+ (C) and
EOMES- (D) NK cells of WT (n=10) and Nkrp1b-/- (n=5) mice injected with Clr-b KO
tumours.
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Figure 17: CD107a expression by TINK cells.
A and B, graphical representation of mean CD107a production by EOMES+ (A) and
EOMES- (B) TINK cells of WT (n=4) and Nkrp1b-/- (n=1) mice injected with WT
tumours. C and D, graphical representation of mean CD107a production by EOMES+
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Clr-b KO tumours.
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Figure 18: IFNγ production by TINK cells.
A and B, graphical representation of mean IFNγ production by EOMES+ (A) and
EOMES- (B) TINK cells of WT (n=4) and Nkrp1b-/- (n=1) mice injected with WT
tumours. C and D, graphical representation of mean IFNγ production by EOMES+ (C)
and EOMES- (D) TINK cells of WT (n=8) and Nkrp1b-/- (n=3) mice injected with Clr-b
KO tumours.
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DISCUSSION
The anti-tumour responses of NK cells can be attributed to their cytolytic
functions and their lack of need of prior priming in order to produce an immune response.
High levels of TINK cells in most solid tumours are linked to better cancer prognosis, 68
however, the TME can cause diminished NK cell activity.72 In this study, WT and NKRP1B deficient B6 mice injected with E0771 and E0771 Clr-b-/- mammary
adenocarcinoma cells were used as models to determine the role of the NKR-P1B:Clr-b
inhibitory axis in the detection and elimination of mammary tumours. NK cells have been
previously shown to infiltrate E0771 tumours,95 and E0771 tumours have been linked to
tumour immunoediting.95 Additionally, E0771 cells lacking MHC I expression were more
prone to elimination by NK cells in comparison to WT E0771 cells.95 NKR-P1B and its
ligand Clr-b have been shown to regulate cancer immune responses,38 and the
interactions between them is essential for MHC I-independent NK cell education.27 Here,
we show that Nkrp1b-/- mice injected with E0771 mammary tumour cells remained
tumour-free longer than their WT counterparts (Figure 3A). Clr-b is expressed on WT
E0771 cells, and disruption of NKR-P1B:Clr-b interactions would prevent signalling to
this inhibitory receptor that would cause NK cell inhibition, resulting in reduced growth.
This is due to the NK cells recognizing the tumour cells as altered cells and employing
cytotoxic responses via missing-self recognition. Previously, Ly49 deficient mice
injected with MHC I deficient E0771 tumour cells were shown to develop larger tumours
quicker than WT mice injected with the same cells.95 This is also expected of Nkrp1b-/mice injected with Clr-b deficient E0771 cells due to the loss of Clr-b-dependent
missing-self recognition in these mice. Although, our results did not show a notable
difference between tumour onset and growth in WT and Nkrp1b-/- mice (Figure 3B),
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nevertheless, Nkrp1b-/- mice were less resistant to Clr-b KO tumour growth compared to
WT tumours, indicative of an impaired missing-self response in Nkrp1b-/- mice where
they are unable to detect and respond against Clr-b-deficient targets, as previously seen
by Rahim et al.38
Tumour cell immunoevasion can occur by a variety of different factors which
diminish NK cell response. The loss of EOMES expression is linked to NK cell
exhaustion and diminished NK cytolytic responses.73,97 Our results show that NKR-P1Bdeficiency in the KO mice is linked to a lower frequency of EOMES+ TINK cells in mice
injected Clr-b KO tumour cells (Figure 4D). The decreased proportions of EOMES+
TINK cells in Nkrp1b-/- mice injected with KO tumours can be explained by the loss of
MHC I-independent NK cell education, meaning that these TINKs likely possess a more
immature phenotype. In fact, this is supported by the observed increase of CD27 SP
proportions of TINK cells of Nkrp1b-/- mice, regardless of tumour type (Figure 13).
The activation status and proliferative capacity of TINKs were determined by
observing Granzyme B and Ki67 expression in EOMES+ and EOMES- subsets of WT
and Nkrp1b-/- mice. Granzyme B expression did not appear to differ in TINK EOMES+
and EOMES- subsets between the mice strains, indicating that TINK activation status
remains similar regardless of NKR-P1B expression. Conversely, the proliferation
phenotype of Nkrp1b-/- TINK cells, as determined by Ki67 expression, markedly
decreased in EOMES+ and EOMES- subsets compared to WT counterparts, regardless of
tumour type (Figure 6). This downregulation of Ki67 may be linked to the loss of
EOMES expression in Nkrp1b-/- TINKs of mice injected with KO tumours (Figure 4), or
due to the reduced tumour burden, leading to a reduction in proliferation, in Nkrp1b-/-
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mice injected with WT tumours. Alternatively, the upregulation of Ki67 has been
previously linked to lower circulating NK cell levels and worse disease prognosis in
systemic lupus erythematosus,104 indicating that our observed reduction in Ki67
expression in Nkrp1b-/- TINKs may be beneficial to NK effector function.
The expression levels of several NK receptors, adhesion molecules, and other
markers of immunological exhaustion pointed to an altered phenotype in Nkrp1b-/tumour-bearing mice in comparison to their WT counterparts. Receptor expression of
Nkp46, NKG2D, and DNAM-1 activating receptors were used as activation markers of
TINK cells. Nkp46 expression did not differ significantly between WT and Nkrp1b -/TINKs (Figure 7), however, NKG2D and DNAM-1 expression appears to be elevated in
Nkrp1b-/- TINKs regardless of tumour type (Figures 7 and 8), especially obvious in the
case of DNAM-1. Additionally, the expression of inhibitory receptor Ly49C/I was
measured in the different mice, pointing to decreased expression in Nkrp1b-/- compared to
WT TINK cells (Figure 9). This data points to an increased activation potential in the
tumour-infiltrating NK cells of Nkrp1b-/- mice, due to the loss of the NKR-P1B receptor.
Expression of immune exhaustion markers KLR-G-1 and PD-1 were measured to
determine the exhaustion phenotypes of EOMES+ and EOMES- TINK cells from WT
and Nkrp1b-/- mice. The results indicate that there is an increased proportion of EOMESTINK cells in Nkrp1b-/- mice expressing these exhaustion markers compared to WT mice
(Figure 10). This data is indicative of EOMES- TINK cells presenting immune
exhaustion phenotypes, with higher proportions in Nkrp1b-/- mice. This alludes to NKRP1B playing a role in regulating the exhaustion of NK cells. Additional evidence for the
role of NKR-P1B in the regulation of immune exhaustion is the elevated expression of
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CD49a on TINK cells of NKR-P1B-deficient mice (Figure 11), in the presence of Clr-b.
When mice were injected with Clr-b-deficient tumour cells, NKR-P1B-deficient mice did
not demonstrate an increase in CD49a expression compared to WT mice (Figure 11),
however, both WT and Nkrp1b-/- mice showed the same expression levels of CD49a as
the Nkrp1b-/- mouse injected with Clr-b-sufficient tumour cells, further suggesting that
the NKR-P1B:Clr-b axis plays a role in regulating NK cell immune exhaustion.
Additionally, myeloid-derived suppressor cells contribute to the
immunosuppressive nature of the tumour microenvironment, leading to further NK cell
exhaustion.105 MDSC expression is linked to increased TGF-β production, previously
shown to decrease NK cytolytic function.106 Furthermore, flow cytometry detected the
expression of Clr-b by MDSCs (Figure 14G), which can inhibit NK function by
signalling through the NKR-P1B receptor independently of Clr-b expression in tumour
cells.
In vitro stimulation of splenic and tumour-infiltrating NK cells from tumourbearing mice was done to determine NK cell degranulative and proinflammatory
capacity. Stimulation of splenic NK cells with PMA and ionomycin, IL-12 and IL-18,
and YAC-1 showed that EOMES+ NK cells had increased degranulative and
proinflammatory activity, while EOMES- NK cells (which already expressed high levels
of CD107a) were not able to maintain such increased activity (Figures 15 and 16).
Similarly, the stimulation of TINK cells showed that the EOMES- populations displayed
an exhausted phenotype that could not degranulate or produce IFNγ to the same extent as
the EOMES+ population (Figures 17 and 18). Additionally, splenic and tumour-
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infiltrating NK cells from Nkrp1b-/- mice were less responsive to stimulation than the WT
mice, consistent to the higher exhaustion seen in the absence of NKR-P1B.
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CONCLUSION AND FUTURE DIRECTIONS
Our data suggest that NKR-P1B plays a complex role in tumour regulation. The
data presented provides evidence of NKR-P1B involvement in mammary
adenocarcinoma immunosurveillance. Although it is expected that the loss of the NKRP1B receptor in mice would lead to an overall decrease in tumour immunoevasion, as
well as an increase in NK cell cytolytic function, it is evident that the loss of this receptor
presents a more complex phenotype. This phenotype could be attributed to the NKRP1B:Clr-b axis regulating NK cell exhaustion (possibly due to increased activation), as
well as other factors in the TME, such as MDSCs, altering NK anti-tumour functions.
Future steps include increasing the population sizes to determine significance, and further
investigating NK cell phenotype in our cancer models. As well, the role of the NKRP1B:Clr-b axis in the suppression of NK cell activity by MDSCs in TME warrants further
investigation. Further research into the NKR-P1B:Clr-b axis would be beneficial in order
to better understand its human analogue, NKR-P1A:LLT-1, and allow for the design of
novel immunotherapy regimens.
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